

Table SI. Patients stratified by European Society for Therapeutic Radiology and Oncology/European Organization for Research and Treatment of Cancer classification.

Category	of % (n)	Median overall survival Months	P-value	Median progression-free survival Months	P-value
oligometastatic disease					
Synchronous oligometastasis (reference)	40 (52)	42.8	-	12.5	-
Metachronous oligorecurrence	29 (38)	27.3	0.89	20.1	0.49
Metachronous oligoprogression	8 (10)	45.2	0.71	24.3	0.23
Repeat oligorecurrence	6 (8)	Not reached	0.19	23.9	0.17
Repeat oligopersistence	1 (1)	TFP	N/A	TFP	N/A
Repeat oligoprogression	4 (5)	8.3	<0.01	3.9	<0.01
Induced oligorecurrence	2 (2)	TFP	N/A	TFP	N/A
Induced oligopersistence	3 (4)	17.0	0.24	3.8	0.40
Induced oligoprogression	8 (10)	31.7	0.20	7.0	0.16

TFP, too few patients.

Table SII. Patients stratified by type of systemic therapy received.

Adjuvant systemic therapy	% (n)
None	26 (34)
Chemotherapy alone	18 (23)
Hormonal therapy alone or with androgen receptor inhibitor or CDK4/6 inhibitor	15 (19)
Immunotherapy alone	12 (15)
Chemotherapy combined with biologically targeted therapy	10 (13)
Biologically targeted therapy alone	9 (12)
Chemoimmunotherapy	9 (12)
Hormonal therapy with chemotherapy or targeted therapy	2 (2)

Table SIII. Univariate analyses of potential prognostic factors.

Variable	Median overall survival		Median progression-free survival	
	Months	P-value	Months	P-value
Age (years)		<0.01		<0.01
<60	Not reached		23.9	
60-79	39.8		10.4	
≥80	19.7		9.3	
Sex (F vs. M)		0.19		0.21
Male	45.3		12.9	
Female	28.9		10.4	
ECOG performance status (0 vs. 1 vs. 2 vs. 3-4)		<0.01		0.07
0	Not reached		22.3	
1	28.9		10.4	
2	18.6		8.8	
3-4	12.8		10.1	
Category of oligometastatic disease (induced vs. other)		0.07		0.05
<i>De novo</i> oligometastases (reference)	43.9		14.4	
Recurrent oligometastases	17.9	0.84	9.3	0.75
Induced oligometastases	31.7	0.07	8.8	0.04
Primary tumor (breast, prostate or kidney vs. other)		<0.01		<0.01
Lung	43.9	0.02	10.1	<0.01
Prostate (reference)	Not reached		46.2	
Breast	82.9	0.19	14.4	0.11
Colorectal	39.8	0.02	10.4	<0.01
Endometrial	31.7	<0.01	7.0	0.03
Other	24.3	<0.01	8.3	<0.01
Metastasis location				
Bone	37.9	0.33	21.0	0.30
Brain	29.8	0.42	7.1	0.34
Lung	39.8	0.51	15.9	0.95
Distant lymph nodes	45.2	0.75	15.8	0.63
Liver	9.9	0.11	8.7	0.12
Adrenal gland	12.2	0.61	9.3	0.40
Albumin (g/dl;continuous)		0.03		<0.01
≥3.4	45.2		13.8	
2.4-3.3	18.5		9.6	
<2.4	7.1		3.0	
Unknown	31.7		26.9	
No. of metastases treated				
0	31.7	0.46	12.9	0.93
1 (reference)	45.2		12.5	
2 to 5	32.3	0.20	10.9	0.05
Active primary tumor requiring treatment		0.35		0.67
No (reference)	33.0		8.3	
Yes	53.8		12.9	
Post-radiation systemic therapy		0.22		0.97
No (reference)	43.9		8.3	
Yes	37.9		12.9	